{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:32:26Z","timestamp":1789162346387,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s12185-011-0924-6","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T10:06:32Z","timestamp":1315389992000},"page":"303-306","source":"Crossref","is-referenced-by-count":14,"title":["The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia"],"prefix":"10.1007","volume":"94","author":[{"given":"Filip","family":"Razga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Racil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Buresova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Klamova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Zackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Dvorakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclava","family":"Polivkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Cetkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,8]]},"reference":[{"key":"924_CR1","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739\u201345.","journal-title":"Blood"},{"key":"924_CR2","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064\u201372.","journal-title":"Blood"},{"key":"924_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2008;83:258\u201364.","journal-title":"Clin Pharmacol Ther"},{"key":"924_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","volume":"25","author":"C Hirayama","year":"2008","unstructured":"Hirayama C, Watanabe H, Nakashima R, et al. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res. 2008;25:827\u201335.","journal-title":"Pharm Res"},{"key":"924_CR5","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28:2761\u20137.","journal-title":"J Clin Oncol"},{"key":"924_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ajh.21722","volume":"85","author":"Z Racil","year":"2010","unstructured":"Racil Z, Razga F, Buresova L, et al. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. Am J Hematol. 2010;85:525\u20138.","journal-title":"Am J Hematol"},{"key":"924_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/10428194.2010.533220","volume":"52","author":"Z Racil","year":"2011","unstructured":"Racil Z, Razga F, Polakova KM, et al. Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types. Leuk lymphoma. 2011;52:331\u20134.","journal-title":"Leuk lymphoma"},{"key":"924_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/leu.2010.86","volume":"24","author":"A Bazeos","year":"2010","unstructured":"Bazeos A, Marin D, Reid AG, et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia. 2010;24:1243\u20135.","journal-title":"Leukemia"},{"key":"924_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3324\/haematol.2010.033290","volume":"96","author":"JR Engler","year":"2011","unstructured":"Engler JR, Zannettino AC, Bailey CG, et al. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica. 2011;96:213\u201320.","journal-title":"Haematologica"},{"key":"924_CR10","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-011-0924-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0924-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:01:42Z","timestamp":1559451702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-011-0924-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s12185-011-0924-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}